Nuvation Bio Earnings Call: IBTROZI Surge, Long Runway

Nuvation Bio Inc ((NUVB)) has held its Q4 earnings call. Read on for the main highlights of the call.

Nuvation Bio’s latest earnings call struck a cautiously optimistic tone, mixing impressive clinical and commercial traction for IBTROZI and a fortified balance sheet with frank acknowledgment of short‑term revenue friction, high operating spend, and long timelines for key late‑stage programs that could test investor patience.

U.S. Approval and Launch Velocity for IBTROZI

IBTROZI secured full U.S. FDA approval on June 11, 2025, for advanced ROS1‑positive NSCLC, marking a pivotal commercial milestone for Nuvation Bio. Management highlighted brisk uptake, with 432 new patients starting therapy in 2025, including 216 in Q4, and prescription trends running roughly six times faster than the last two ROS1 TKI launches over comparable periods.

Clinical Efficacy and Durability Underpinning IBTROZI

The company emphasized compelling durability data in TKI‑naive patients, with a pooled median duration of response of 50 months and a previously reported confirmed overall response rate of 89%. Strong intracranial activity, including a cited 66% intracranial response rate in a second‑line setting, reinforces IBTROZI’s profile in a population where brain metastases are a major driver of progression.

Tolerability Supports Broader Development

Nuvation Bio reported a favorable safety profile from a clinical database of 337 advanced ROS1 patients, with only one discontinuation linked to the six most common adverse events, or roughly 0.3%. This tolerability has enabled expansion into earlier‑stage disease, including dosing of the first patient in the TRUST‑IV adjuvant Phase III study and support for global regulatory submissions.

Global Partnerships and Ex‑U.S. Expansion

The company has secured approvals in China and Japan, extending IBTROZI’s geographic footprint beyond the U.S. A partnership with Eisai covers Europe and select ex‑U.S. markets, featuring about $60 million upfront, an additional payment tied to European approval, sizable sales milestones, and double‑digit to high‑teens royalties that collectively lift ex‑U.S. deal value toward $520 million.

Revenue Picture: Early Contribution but Mixed Signals

Total revenue reached $41.9 million in Q4 2025 and $62.9 million for the full year, including milestones and collaboration income. IBTROZI’s net U.S. product revenue, still in an early launch phase, totaled $15.7 million in Q4 and $24.7 million for 2025, giving investors a first concrete look at the drug’s commercial contribution.

Cash Strength and Path to Profitability

Nuvation Bio ended 2025 with $529.2 million in cash, cash equivalents and marketable securities, bolstered by the Eisai upfront payment. Management stated that, under current operating plans, this cash runway is sufficient to reach profitability without additional external financing, a notable de‑risking point for shareholders.

Safusidenib: Advancing in IDH1‑Mutant Glioma

Safusidenib continues to advance as Nuvation’s second pillar, with Phase II data in low‑grade IDH1‑mutant glioma showing median progression‑free survival not yet reached, about 12% progression at 24 months, and a 44% confirmed response rate in 27 patients. In high‑grade glioma, Phase I results included a 17% response rate and some durable complete responses, supporting the launch of the SIGMA Phase III trial and a non‑pivotal oligodendroglioma cohort.

Launch Execution and Market Access Foundations

Operationally, the company reported engagement with all top‑tier target accounts and IBTROZI prescriptions across all 47 sales territories, with multiple repeat prescribers. Broad payer coverage aligned to the label and specialty pharmacy inventories of roughly two to four weeks suggest that access and supply dynamics are largely tracking underlying demand.

Revenue Lagging Patient Starts Highlights Mix Issue

Despite 432 new patient starts in 2025, IBTROZI’s net U.S. product revenue remained modest, underscoring a gap between clinical adoption and near‑term sales. Management attributed this primarily to an early patient mix skewed toward heavily pretreated, later‑line individuals who discontinue therapy more quickly, which dampens revenue recognition per start.

Elevated Operating Spend Weighs on Near Term

Full‑year 2025 research and development expenses reached $115.1 million, while selling, general and administrative costs totaled $151.6 million. These high levels of spending reflect aggressive investment behind IBTROZI’s launch and the broader pipeline, but they also heighten the pressure on management to translate clinical momentum into sustainable earnings.

Gross‑to‑Net and Pricing Headwinds

The company reported a gross‑to‑net adjustment of roughly 25% as of Q4 2025 and expects this figure to tick higher before stabilizing as access broadens. That trajectory implies some pressure on net realized pricing over time, as additional contracts, rebates and patient support measures are layered into the commercial model.

Safusidenib Risks and Long Development Timelines

While safusidenib’s efficacy signals are encouraging, management acknowledged dermatologic side effects such as alopecia, arthralgia and skin hyperpigmentation, with an approximate 8% drug‑related discontinuation rate at the pivotal dose. The SIGMA Phase III study, a progression‑free survival trial without a planned interim readout and an expected completion in 2029, underscores the long horizon before this asset can meaningfully impact revenue.

Pipeline Setback in DDC Modality

The discontinuation of NUV‑1511, Nuvation Bio’s first drug‑drug conjugate program, in Q4 2025 marked a setback for the company’s broader platform ambitions. While management stressed that insights from this effort will inform next‑generation preclinical candidates, the move highlights the inherent risk in early‑stage innovation and the need to reallocate resources carefully.

Visibility Challenges and Market Risk Factors

Management cautioned that visibility into the full patient mix remains limited, as not all cases are captured through hub data, and that seasonal variability, particularly in Q4, can affect quarterly trends. Potential competitive entrants in the ROS1 space later in 2026 add another layer of uncertainty around IBTROZI’s future uptake and the cadence of revenue growth.

Revenue Quality and Milestone Contributions

A significant portion of 2025 revenue came from milestones and collaboration payments, including a major payment tied to a Japan approval and the Eisai upfront. Investors are likely to scrutinize future quarters for cleaner separation of recurring product revenue versus one‑time partnership income to better assess IBTROZI’s underlying sales trajectory.

Outlook and Key Milestones Ahead

The company did not offer formal 2026 revenue guidance but pointed to operational run‑rate metrics, such as a sustained pace of more than 200 new IBTROZI patient starts per quarter and solid payer coverage, as indicators of momentum. On the clinical side, long‑term value hinges on the safusidenib program, with a non‑pivotal oligodendroglioma cohort potentially reading out in 2027 and the larger SIGMA Phase III trial slated to deliver data in 2029, all supported by a cash position that management believes is sufficient to reach profitability.

Nuvation Bio’s earnings call painted a picture of a company with a differentiated lung cancer drug gaining traction, substantial cash resources, and a promising but lengthy development path in neuro‑oncology. For investors, the story now turns on whether early IBTROZI adoption and disciplined execution can offset near‑term revenue noise, elevated expenses, and the long wait for pivotal safusidenib data.